IL129558A - History of apothilone and pharmaceuticals and herbal preparations containing them - Google Patents
History of apothilone and pharmaceuticals and herbal preparations containing themInfo
- Publication number
- IL129558A IL129558A IL12955897A IL12955897A IL129558A IL 129558 A IL129558 A IL 129558A IL 12955897 A IL12955897 A IL 12955897A IL 12955897 A IL12955897 A IL 12955897A IL 129558 A IL129558 A IL 129558A
- Authority
- IL
- Israel
- Prior art keywords
- epothilone
- methanol
- culture
- compositions
- epothilones
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 16
- 150000003883 epothilone derivatives Chemical class 0.000 title claims description 14
- 229930013356 epothilone Natural products 0.000 claims abstract description 30
- BEFZAMRWPCMWFJ-JRBBLYSQSA-N Epothilone C Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C=C\C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C BEFZAMRWPCMWFJ-JRBBLYSQSA-N 0.000 claims abstract description 10
- BEFZAMRWPCMWFJ-UHFFFAOYSA-N desoxyepothilone A Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC=CCC1C(C)=CC1=CSC(C)=N1 BEFZAMRWPCMWFJ-UHFFFAOYSA-N 0.000 claims abstract description 10
- XOZIUKBZLSUILX-SDMHVBBESA-N Epothilone D Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C XOZIUKBZLSUILX-SDMHVBBESA-N 0.000 claims abstract description 9
- XOZIUKBZLSUILX-UHFFFAOYSA-N desoxyepothilone B Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC(C)=CCC1C(C)=CC1=CSC(C)=N1 XOZIUKBZLSUILX-UHFFFAOYSA-N 0.000 claims abstract description 9
- BEFZAMRWPCMWFJ-QJKGZULSSA-N epothilone C Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 BEFZAMRWPCMWFJ-QJKGZULSSA-N 0.000 claims abstract description 9
- XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 16
- 239000003085 diluting agent Substances 0.000 claims description 4
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 claims description 3
- 239000000824 cytostatic agent Substances 0.000 claims description 2
- 230000001085 cytostatic effect Effects 0.000 claims description 2
- 238000003898 horticulture Methods 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 claims 2
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 abstract description 40
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 96
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 239000011347 resin Substances 0.000 description 18
- 229920005989 resin Polymers 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000003480 eluent Substances 0.000 description 14
- FCCNKYGSMOSYPV-DEDISHTHSA-N (-)-Epothilone E Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(CO)sc2)/C)OC(=O)C[C@H](O)C1(C)C FCCNKYGSMOSYPV-DEDISHTHSA-N 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 230000036983 biotransformation Effects 0.000 description 12
- FCCNKYGSMOSYPV-UHFFFAOYSA-N epothilone E Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC2OC2CC1C(C)=CC1=CSC(CO)=N1 FCCNKYGSMOSYPV-UHFFFAOYSA-N 0.000 description 12
- FCCNKYGSMOSYPV-OKOHHBBGSA-N epothilone e Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 FCCNKYGSMOSYPV-OKOHHBBGSA-N 0.000 description 12
- UKIMCRYGLFQEOE-RLHMMOOASA-N (-)-Epothilone F Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(CO)sc2)/C)OC(=O)C[C@H](O)C1(C)C UKIMCRYGLFQEOE-RLHMMOOASA-N 0.000 description 9
- UKIMCRYGLFQEOE-UHFFFAOYSA-N Epothilone F Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC2(C)OC2CC1C(C)=CC1=CSC(CO)=N1 UKIMCRYGLFQEOE-UHFFFAOYSA-N 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- UKIMCRYGLFQEOE-RGJAOAFDSA-N epothilone f Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 UKIMCRYGLFQEOE-RGJAOAFDSA-N 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 8
- 239000000287 crude extract Substances 0.000 description 8
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 8
- 238000000855 fermentation Methods 0.000 description 7
- 230000004151 fermentation Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 230000008033 biological extinction Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 238000006116 polymerization reaction Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 101150041968 CDC13 gene Proteins 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 239000005030 aluminium foil Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 239000001117 sulphuric acid Substances 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 235000011148 calcium chloride Nutrition 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- LMSDCGXQALIMLM-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;iron Chemical compound [Fe].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O LMSDCGXQALIMLM-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- -1 CH3 Epothilones Chemical group 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 241001532577 Sorangium Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000012505 colouration Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- FFHWGQQFANVOHV-UHFFFAOYSA-N dimethyldioxirane Chemical compound CC1(C)OO1 FFHWGQQFANVOHV-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000862997 Sorangium cellulosum Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000013587 production medium Substances 0.000 description 1
- 125000002577 pseudohalo group Chemical group 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- VAVPGQSSOJBZIP-UHFFFAOYSA-N sodium;iron(3+) Chemical compound [Na+].[Fe+3] VAVPGQSSOJBZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
- A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
- A01N43/78—1,3-Thiazoles; Hydrogenated 1,3-thiazoles
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/20—Bacteria; Substances produced thereby or obtained therefrom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/167—Heterorings having sulfur atoms as ring heteroatoms, e.g. vitamin B1, thiamine nucleus and open chain analogs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Biotechnology (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Microbiology (AREA)
- Agronomy & Crop Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Oncology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Silicon Polymers (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Steroid Compounds (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19647580 | 1996-11-18 | ||
| DE19707506 | 1997-02-25 | ||
| PCT/EP1997/006442 WO1998022461A1 (de) | 1996-11-18 | 1997-11-18 | Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL129558A0 IL129558A0 (en) | 2000-02-29 |
| IL129558A true IL129558A (en) | 2001-10-31 |
Family
ID=26031383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12955897A IL129558A (en) | 1996-11-18 | 1997-11-18 | History of apothilone and pharmaceuticals and herbal preparations containing them |
Country Status (24)
| Country | Link |
|---|---|
| US (6) | US7067544B2 (ru) |
| EP (2) | EP0941227B2 (ru) |
| JP (1) | JP4274583B2 (ru) |
| KR (1) | KR100538095B1 (ru) |
| CN (2) | CN1196698C (ru) |
| AT (2) | ATE267197T1 (ru) |
| AU (1) | AU753546B2 (ru) |
| BR (1) | BR9713363B1 (ru) |
| CA (1) | CA2269118C (ru) |
| CY (1) | CY2542B1 (ru) |
| CZ (2) | CZ296164B6 (ru) |
| DE (2) | DE59712968D1 (ru) |
| DK (2) | DK1367057T3 (ru) |
| ES (2) | ES2221692T5 (ru) |
| HK (2) | HK1022314A1 (ru) |
| HU (1) | HU229833B1 (ru) |
| IL (1) | IL129558A (ru) |
| NO (1) | NO319984B1 (ru) |
| NZ (1) | NZ335383A (ru) |
| PL (1) | PL193229B1 (ru) |
| PT (2) | PT941227E (ru) |
| RU (1) | RU2198173C2 (ru) |
| TW (1) | TW408119B (ru) |
| WO (1) | WO1998022461A1 (ru) |
Families Citing this family (176)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1440973A3 (de) | 1995-11-17 | 2004-10-20 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Epothilonderivate, Herstellung und Mittel |
| US5969145A (en) * | 1996-08-30 | 1999-10-19 | Novartis Ag | Process for the production of epothilones and intermediate products within the process |
| HU229833B1 (en) | 1996-11-18 | 2014-09-29 | Biotechnolog Forschung Gmbh | Epothilone d production process, and its use as cytostatic as well as phytosanitary agents |
| DE69734362T2 (de) | 1996-12-03 | 2006-07-20 | Sloan-Kettering Institute For Cancer Research | Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon |
| US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
| US6660758B1 (en) | 1996-12-13 | 2003-12-09 | The Scripps Research Institute | Epothilone analogs |
| US6441186B1 (en) * | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| US6320045B1 (en) | 1997-12-04 | 2001-11-20 | Bristol-Myers Squibb Company | Process for the reduction of oxiranyl epothilones to olefinic epothilones |
| US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
| US6683100B2 (en) | 1999-01-19 | 2004-01-27 | Novartis Ag | Organic compounds |
| US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| FR2775187B1 (fr) | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
| US6399638B1 (en) | 1998-04-21 | 2002-06-04 | Bristol-Myers Squibb Company | 12,13-modified epothilone derivatives |
| US6498257B1 (en) | 1998-04-21 | 2002-12-24 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
| DE19820599A1 (de) | 1998-05-08 | 1999-11-11 | Biotechnolog Forschung Gmbh | Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung |
| DE19826988A1 (de) * | 1998-06-18 | 1999-12-23 | Biotechnolog Forschung Gmbh | Epothilon-Nebenkomponenten |
| NZ508326A (en) * | 1998-06-18 | 2003-10-31 | Novartis Ag | A polyketide synthase and non ribosomal peptide synthase genes, isolated from a myxobacterium, necessary for synthesis of epothiones A and B |
| DE19846493A1 (de) * | 1998-10-09 | 2000-04-13 | Biotechnolog Forschung Gmbh | DNA-Sequenzen für die enzymatische Synthese von Polyketid- oder Heteropolyketidverbindungen |
| NZ511722A (en) * | 1998-11-20 | 2004-05-28 | Kosan Biosciences Inc | Recombinant methods and materials for producing epothilone and epothilone derivatives |
| US6410301B1 (en) | 1998-11-20 | 2002-06-25 | Kosan Biosciences, Inc. | Myxococcus host cells for the production of epothilones |
| US6780620B1 (en) | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
| EP1140928A4 (en) * | 1998-12-23 | 2002-10-02 | Bristol Myers Squibb Co | MICROBIAL CONVERSION METHOD FOR PRODUCING AN EPOTHILONE |
| US6596875B2 (en) | 2000-02-07 | 2003-07-22 | James David White | Method for synthesizing epothilones and epothilone analogs |
| CA2360452C (en) * | 1999-02-22 | 2011-07-26 | Gerhard Hoefle | C-21 modified epothilones |
| US6291684B1 (en) | 1999-03-29 | 2001-09-18 | Bristol-Myers Squibb Company | Process for the preparation of aziridinyl epothilones from oxiranyl epothilones |
| US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| WO2000062778A1 (en) | 1999-04-15 | 2000-10-26 | Bristol-Myers Squibb Co. | Cyclic protein tyrosine kinase inhibitors |
| CA2385528C (en) | 1999-10-01 | 2013-12-10 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| US6518421B1 (en) * | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
| US6593115B2 (en) | 2000-03-24 | 2003-07-15 | Bristol-Myers Squibb Co. | Preparation of epothilone intermediates |
| US6998256B2 (en) | 2000-04-28 | 2006-02-14 | Kosan Biosciences, Inc. | Methods of obtaining epothilone D using crystallization and /or by the culture of cells in the presence of methyl oleate |
| US6589968B2 (en) | 2001-02-13 | 2003-07-08 | Kosan Biosciences, Inc. | Epothilone compounds and methods for making and using the same |
| KR20070092334A (ko) * | 2000-04-28 | 2007-09-12 | 코산 바이오사이언시즈, 인코포레이티드 | 폴리케타이드의 제조방법 |
| UA75365C2 (en) * | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
| GB0029895D0 (en) | 2000-12-07 | 2001-01-24 | Novartis Ag | Organic compounds |
| SK8552003A3 (en) | 2001-01-25 | 2004-06-08 | Bristol Myers Squibb Co | Parenteral formulation containing epothilone analogs |
| NZ526870A (en) | 2001-01-25 | 2005-11-25 | Bristol Myers Squibb Co | Methods of administering epothilone analogs for the treatment of cancer |
| WO2002058699A1 (en) | 2001-01-25 | 2002-08-01 | Bristol-Myers Squibb Company | Pharmaceutical forms of epothilones for oral administration |
| US6893859B2 (en) | 2001-02-13 | 2005-05-17 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
| HUP0303175A2 (hu) | 2001-02-20 | 2003-12-29 | Bristol-Myers Squibb Co. | Epotilonszármazékok alkalmazása makacs tumorok kezelésére alkalmas gyógyszerkészítmény előállítására |
| HUP0400041A2 (hu) | 2001-02-20 | 2004-04-28 | Bristol-Myers Squibb Co. | Epotilonszármazékok alkalmazása makacs tumorok kezelésére szolgáló gyógyszerkészítmények előállítására |
| MXPA03007466A (es) | 2001-02-27 | 2003-12-08 | Gbf Ges F R Biotechnologische | Degradacion de epotilonas y epotilonas substituidas con etileno. |
| CN1511036B (zh) | 2001-02-27 | 2010-05-05 | 诺瓦提斯公司 | 包含信号转导抑制剂和埃坡霉素衍生物的联合形式 |
| CA2440555A1 (en) | 2001-03-14 | 2002-09-19 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| JP2004532888A (ja) | 2001-06-01 | 2004-10-28 | ブリストル−マイヤーズ スクイブ カンパニー | エポチロン誘導体 |
| TWI315982B (en) | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
| TWI287986B (en) * | 2001-12-13 | 2007-10-11 | Novartis Ag | Use of Epothilones for the treatment of the carcinoid syndrome |
| US6884608B2 (en) | 2001-12-26 | 2005-04-26 | Bristol-Myers Squibb Company | Compositions and methods for hydroxylating epothilones |
| KR20040078123A (ko) | 2002-01-14 | 2004-09-08 | 노파르티스 아게 | 에포틸론 및 대사길항물질을 포함하는 조합물 |
| TW200303202A (en) | 2002-02-15 | 2003-09-01 | Bristol Myers Squibb Co | Method of preparation of 21-amino epothilone derivatives |
| WO2003077903A1 (en) | 2002-03-12 | 2003-09-25 | Bristol-Myers Squibb Company | C12-cyano epothilone derivatives |
| DK1483251T3 (da) | 2002-03-12 | 2010-04-12 | Bristol Myers Squibb Co | C3-cyano-epothilon-derivater |
| TW200403994A (en) | 2002-04-04 | 2004-03-16 | Bristol Myers Squibb Co | Oral administration of EPOTHILONES |
| TW200400191A (en) | 2002-05-15 | 2004-01-01 | Bristol Myers Squibb Co | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
| US7405234B2 (en) | 2002-05-17 | 2008-07-29 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
| WO2003105828A1 (en) | 2002-06-14 | 2003-12-24 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| JP2005534332A (ja) * | 2002-07-29 | 2005-11-17 | オプティマー ファーマシューティカルズ、インコーポレイテッド | チアクマイシン生産 |
| ES2281692T3 (es) * | 2002-08-23 | 2007-10-01 | Sloan-Kettering Institute For Cancer Research | Sintesis de epotilones, sus intermediarios, sus analogos y sus usos. |
| TWI291464B (en) | 2002-09-23 | 2007-12-21 | Bristol Myers Squibb Co | Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B |
| CA2501717C (en) * | 2002-10-15 | 2012-09-18 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Use of epothilone derivatives for the treatment of hyperparathyroidism |
| EP1567487A4 (en) | 2002-11-15 | 2005-11-16 | Bristol Myers Squibb Co | OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION |
| CN101177425B (zh) * | 2003-01-28 | 2012-07-18 | 北京华昊中天生物技术有限公司 | 一类新型埃坡霉素化合物及其制备方法和用途 |
| US20050171167A1 (en) | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
| EP1559447A1 (en) | 2004-01-30 | 2005-08-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism |
| US7820702B2 (en) | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
| US7378426B2 (en) | 2004-03-01 | 2008-05-27 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
| US7625923B2 (en) | 2004-03-04 | 2009-12-01 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
| US7696241B2 (en) | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
| SG152225A1 (en) | 2004-04-07 | 2009-05-29 | Novartis Ag | Inhibitors of iap |
| US10675326B2 (en) | 2004-10-07 | 2020-06-09 | The Board Of Trustees Of The University Of Illinois | Compositions comprising cupredoxins for treating cancer |
| KR20070084325A (ko) * | 2004-11-18 | 2007-08-24 | 브리스톨-마이어스 스큅 컴퍼니 | 익사베필론을 포함하는 장용성 코팅된 비드 및 그의 제조방법 |
| EP1824458A1 (en) * | 2004-11-18 | 2007-08-29 | Bristol-Myers Squibb Company | Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof |
| US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| WO2007038459A2 (en) | 2005-09-27 | 2007-04-05 | Novartis Ag | Carboxyamine compounds and their use in the treatment of hdac dependent diseases |
| JP2009516671A (ja) | 2005-11-21 | 2009-04-23 | ノバルティス アクチエンゲゼルシャフト | ｍＴＯＲ阻害剤を使用する神経内分泌腫瘍処置 |
| GB0605120D0 (en) | 2006-03-14 | 2006-04-26 | Novartis Ag | Organic Compounds |
| EP1994412A2 (en) | 2006-03-31 | 2008-11-26 | Brystol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
| MX2008012715A (es) | 2006-04-05 | 2008-10-14 | Novartis Ag | Combinaciones de agentes terapeuticos para el tratamiento de cancer. |
| KR20080109068A (ko) | 2006-04-05 | 2008-12-16 | 노파르티스 아게 | 암을 치료하기 위한 ｂｃｒ-ａｂｌ/ｃ-ｋｉｔ/ｐｄｇｆ-ｒ ｔｋ 억제제를 포함하는 조합물 |
| WO2007128820A1 (en) | 2006-05-09 | 2007-11-15 | Novartis Ag | Combination comprising an iron chelator and an anti-neoplastic agent and use thereof |
| DE602007013441D1 (de) | 2006-09-29 | 2011-05-05 | Novartis Ag | Pyrazolopyrimidine als pi3k-lipidkinasehemmer |
| BRPI0718360A2 (pt) | 2006-12-04 | 2013-11-12 | Univ Illinois | "composições e métodos para o tratamento do câncer com cupredoxinas e dna rico em cpg" |
| JP2010518123A (ja) | 2007-02-08 | 2010-05-27 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ | 癌をキュプレドキシンで予防するための組成物および方法 |
| KR20090110913A (ko) | 2007-02-15 | 2009-10-23 | 노파르티스 아게 | Ｌｂｈ589와 암을 치료하기 위한 다른 치료제와의 조합물 |
| WO2009118292A1 (en) | 2008-03-24 | 2009-10-01 | Novartis Ag | Arylsulfonamide-based matrix metalloprotease inhibitors |
| EA019033B1 (ru) | 2008-03-26 | 2013-12-30 | Новартис Аг | Ингибиторы дезацетилазы в, основанные на гидроксамате |
| CN101362784A (zh) * | 2008-10-06 | 2009-02-11 | 山东大学 | 埃博霉素苷类化合物和以其为活性成分的组合物及其应用 |
| WO2010083617A1 (en) | 2009-01-21 | 2010-07-29 | Oncalis Ag | Pyrazolopyrimidines as protein kinase inhibitors |
| PT2391366E (pt) | 2009-01-29 | 2013-02-05 | Novartis Ag | Benzimidazoles substituídos para o tratamento de astrocitomas |
| GEP20156250B (en) | 2009-06-26 | 2015-02-25 | Novartis Ag | 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| EP2464649A1 (en) | 2009-08-12 | 2012-06-20 | Novartis AG | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
| CA2771432A1 (en) | 2009-08-20 | 2011-02-24 | Novartis Ag | Heterocyclic oxime compounds |
| EA201200321A1 (ru) | 2009-08-26 | 2012-09-28 | Новартис Аг | Тетразамещенные гетероарильные соединения и их применение в качестве модуляторов mdm2 и/или mdm4 |
| PE20121471A1 (es) | 2009-11-04 | 2012-11-01 | Novartis Ag | Derivados de sulfonamida heterociclicos utiles como inhibidores de mek |
| PE20121384A1 (es) | 2009-12-08 | 2012-10-13 | Novartis Ag | Derivados de sulfonamida heterociclicos |
| CU24130B1 (es) | 2009-12-22 | 2015-09-29 | Novartis Ag | Isoquinolinonas y quinazolinonas sustituidas |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| EP3566719A1 (en) | 2010-05-18 | 2019-11-13 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| EP2627648A1 (en) | 2010-09-16 | 2013-08-21 | Novartis AG | 17aHYDROXYLASE/C17,20-LYASE INHIBITORS |
| AU2012207142B2 (en) | 2011-01-20 | 2017-04-27 | Board Of Regents, The University Of Texas System | MRI markers, delivery and extraction systems, and methods of manufacture and use thereof |
| JP2014505088A (ja) | 2011-02-10 | 2014-02-27 | ノバルティス アーゲー | Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物 |
| ES2656218T3 (es) | 2011-04-28 | 2018-02-26 | Novartis Ag | Inhibidores de 17 alfa-hidroxilasa/C17,20-liasa |
| EA201391820A1 (ru) | 2011-06-09 | 2014-12-30 | Новартис Аг | Гетероциклические сульфонамидные производные |
| JP5926374B2 (ja) | 2011-06-10 | 2016-05-25 | メルサナ セラピューティクス，インコーポレイティド | タンパク質−高分子−薬剤コンジュゲート |
| US8859586B2 (en) | 2011-06-20 | 2014-10-14 | Novartis Ag | Cyclohexyl isoquinolinone compounds |
| WO2012175520A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
| MX2013015001A (es) | 2011-06-27 | 2014-03-31 | Novartis Ag | Formas solidas y sales de derivados de tetrahidro-pirido-pirimidin a. |
| CN102863474A (zh) | 2011-07-09 | 2013-01-09 | 陈小平 | 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用 |
| UY34329A (es) | 2011-09-15 | 2013-04-30 | Novartis Ag | Compuestos de triazolopiridina |
| CN102993239A (zh) | 2011-09-19 | 2013-03-27 | 陈小平 | 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物 |
| JP5992054B2 (ja) | 2011-11-29 | 2016-09-14 | ノバルティス アーゲー | ピラゾロピロリジン化合物 |
| IN2014CN04174A (ru) | 2011-12-22 | 2015-09-04 | Novartis Ag | |
| WO2013093850A1 (en) | 2011-12-22 | 2013-06-27 | Novartis Ag | Quinoline derivatives |
| JP2015503516A (ja) | 2011-12-23 | 2015-02-02 | ノバルティス アーゲー | Ｂｃｌ２と結合相手の相互作用を阻害するための化合物 |
| JP2015503517A (ja) | 2011-12-23 | 2015-02-02 | ノバルティス アーゲー | Ｂｃｌ２と結合相手の相互作用を阻害するための化合物 |
| BR112014015339A2 (pt) | 2011-12-23 | 2017-06-13 | Novartis Ag | compostos para inibição da interação de bcl2 com parceiros de ligação |
| MX2014007729A (es) | 2011-12-23 | 2015-01-12 | Novartis Ag | Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace. |
| BR112014015322A2 (pt) | 2011-12-23 | 2017-06-13 | Novartis Ag | compostos e composições para inibir a interação de bcl2 com parceiros de ligação |
| KR101372563B1 (ko) * | 2011-12-26 | 2014-03-14 | 주식회사 삼양바이오팜 | 에포틸론 함유물질로부터 에포틸론 ａ와 ｂ의 추출 및 정제 방법 |
| UY34591A (es) | 2012-01-26 | 2013-09-02 | Novartis Ag | Compuestos de imidazopirrolidinona |
| NZ701626A (en) | 2012-05-15 | 2016-02-26 | Novartis Ag | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 |
| JP6078640B2 (ja) | 2012-05-15 | 2017-02-08 | ノバルティス アーゲー | Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体 |
| CA2871715A1 (en) | 2012-05-15 | 2013-11-21 | Novartis Ag | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 |
| CN104334529B (zh) | 2012-05-15 | 2017-03-15 | 诺华股份有限公司 | 用于抑制abl1、abl2和bcr‑abl1的活性的化合物和组合物 |
| WO2013175417A1 (en) | 2012-05-24 | 2013-11-28 | Novartis Ag | Pyrrolopyrrolidinone compounds |
| BR112014031421A2 (pt) | 2012-06-15 | 2017-06-27 | Brigham & Womens Hospital Inc | composições para tratamento de câncer e métodos para produção das mesmas |
| PL2903968T3 (pl) | 2012-10-02 | 2017-05-31 | Gilead Sciences, Inc. | Inhibitory demetylaz histonowych |
| CN104768962B (zh) | 2012-11-17 | 2017-04-05 | 北京市丰硕维康技术开发有限责任公司 | 离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物 |
| TW201422625A (zh) | 2012-11-26 | 2014-06-16 | Novartis Ag | 二氫－吡啶并－□衍生物之固體形式 |
| JP6334553B2 (ja) | 2012-12-10 | 2018-05-30 | メルサナ セラピューティクス，インコーポレイティド | タンパク質−高分子−薬剤コンジュゲート |
| EP2931316B1 (en) | 2012-12-12 | 2019-02-20 | Mersana Therapeutics, Inc. | Hydroxyl-polymer-drug-protein conjugates |
| JO3464B1 (ar) | 2013-01-15 | 2020-07-05 | Astellas Pharma Europe Ltd | التركيبات الخاصة بمركبات التياكوميسين |
| WO2014115080A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
| EP2948451B1 (en) | 2013-01-22 | 2017-07-12 | Novartis AG | Substituted purinone compounds |
| WO2014128612A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Quinazolin-4-one derivatives |
| JP6514117B2 (ja) | 2013-02-27 | 2019-05-15 | エピセラピューティクス アーペーエス | ヒストン脱メチル化酵素の阻害剤 |
| US20150018376A1 (en) | 2013-05-17 | 2015-01-15 | Novartis Ag | Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof |
| EP3007692A1 (en) | 2013-06-11 | 2016-04-20 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor |
| UY35675A (es) | 2013-07-24 | 2015-02-27 | Novartis Ag | Derivados sustituidos de quinazolin-4-ona |
| WO2015022664A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
| US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
| WO2015022663A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
| SG11201600707QA (en) | 2013-09-22 | 2016-02-26 | Calitor Sciences Llc | Substituted aminopyrimidine compounds and methods of use |
| EP3054991B1 (en) | 2013-10-11 | 2019-04-03 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| US10316080B2 (en) | 2013-10-11 | 2019-06-11 | Asana Biosciences, Llc | Protein-polymer-drug conjugates |
| JP6517319B2 (ja) | 2014-03-28 | 2019-05-22 | キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ | 置換されたヘテロアリール化合物および使用方法 |
| EP3126345A1 (en) | 2014-03-31 | 2017-02-08 | Gilead Sciences, Inc. | Inhibitors of histone demethylases |
| AU2015241198A1 (en) | 2014-04-03 | 2016-11-17 | Invictus Oncology Pvt. Ltd. | Supramolecular combinatorial therapeutics |
| KR20170040805A (ko) | 2014-08-27 | 2017-04-13 | 길리애드 사이언시즈, 인코포레이티드 | 히스톤 데메틸라제를 억제하기 위한 화합물 및 방법 |
| WO2017044434A1 (en) | 2015-09-11 | 2017-03-16 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
| WO2018004338A1 (en) | 2016-06-27 | 2018-01-04 | Tagworks Pharmaceuticals B.V. | Cleavable tetrazine used in bio-orthogonal drug activation |
| US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
| US10772971B2 (en) | 2017-06-22 | 2020-09-15 | Mersana Therpeutics, Inc. | Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates |
| EP3710006A4 (en) | 2017-11-19 | 2021-09-01 | Sunshine Lake Pharma Co., Ltd. | SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE |
| US10751339B2 (en) | 2018-01-20 | 2020-08-25 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
| CA3099419A1 (en) | 2018-05-04 | 2019-11-07 | Tagworks Pharmaceuticals B.V. | Tetrazines for high click conjugation yield in vivo and high click release yield |
| EP3788032B1 (en) | 2018-05-04 | 2024-01-24 | Tagworks Pharmaceuticals B.V. | Compounds comprising a linker for increasing transcyclooctene stability |
| JP2022513400A (ja) | 2018-10-29 | 2022-02-07 | メルサナ セラピューティクス インコーポレイテッド | ペプチド含有リンカーを有するシステイン操作抗体－薬物コンジュゲート |
| FR3087650B1 (fr) | 2018-10-31 | 2021-01-29 | Bio Even | Flavine adenine dinucleotide (fad) pour son utilisation pour la prevention et/ou le traitement de cancer |
| JP2022537543A (ja) | 2019-06-17 | 2022-08-26 | タグワークス ファーマシューティカルス ビー．ブイ． | 高速で且つ効率的なクリック放出の為の化合物 |
| IL289094A (en) | 2019-06-17 | 2022-02-01 | Tagworks Pharmaceuticals B V | Tetrazines for increasing the speed and yield of the "click release" reaction |
| EP4399283A2 (en) | 2021-09-06 | 2024-07-17 | Veraxa Biotech GmbH | Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes |
| WO2023094525A1 (en) | 2021-11-25 | 2023-06-01 | Veraxa Biotech Gmbh | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
| EP4186529A1 (en) | 2021-11-25 | 2023-05-31 | Veraxa Biotech GmbH | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
| WO2023104941A1 (en) | 2021-12-08 | 2023-06-15 | European Molecular Biology Laboratory | Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates |
| EP4314031B1 (en) | 2022-02-15 | 2024-03-13 | Tagworks Pharmaceuticals B.V. | Masked il12 protein |
| WO2024013724A1 (en) | 2022-07-15 | 2024-01-18 | Pheon Therapeutics Ltd | Antibody-drug conjugates |
| WO2024080872A1 (en) | 2022-10-12 | 2024-04-18 | Tagworks Pharmaceuticals B.V. | Strained bicyclononenes |
| WO2024153789A1 (en) | 2023-01-20 | 2024-07-25 | Basf Se | Stabilized biopolymer composition, their manufacture and use |
| WO2024191293A1 (en) | 2023-03-10 | 2024-09-19 | Tagworks Pharmaceuticals B.V. | Trans-cyclooctene with improved t-linker |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0358606A3 (de) | 1988-09-09 | 1990-10-31 | Gesellschaft für Biotechnologische Forschung mbH (GBF) | Mikrobiologisches Verfahren zur Herstellung agrarchemisch verwendbarer mikrobizider makrozyklischer Lactonderivate |
| GB8909737D0 (en) * | 1989-04-27 | 1989-06-14 | Shell Int Research | Thiazole derivatives |
| DE4138042C2 (de) * | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel |
| CA2157190A1 (en) * | 1993-03-05 | 1994-09-15 | Wilfried Fischer | Crystalline cyclodextrin inclusion complexes of ranitidine hydrochloride and process for their preparation |
| WO1995018798A1 (en) | 1994-01-11 | 1995-07-13 | The Scripps Research Institute | Chemical switching of taxo-diterpenoids between low solubility active forms and high solubility inactive forms |
| EP1440973A3 (de) | 1995-11-17 | 2004-10-20 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Epothilonderivate, Herstellung und Mittel |
| DE19542986A1 (de) * | 1995-11-17 | 1997-05-22 | Biotechnolog Forschung Gmbh | Epothilon-Derivate und deren Verwendung |
| DE19639456A1 (de) | 1996-09-25 | 1998-03-26 | Biotechnolog Forschung Gmbh | Epothilon-Derivate, Herstellung und Mittel |
| JP2001500851A (ja) | 1996-08-30 | 2001-01-23 | ノバルティス アクチエンゲゼルシャフト | エポシロンの製造法および製造過程中に得られる中間生産物 |
| DE19645362A1 (de) | 1996-10-28 | 1998-04-30 | Ciba Geigy Ag | Verfahren zur Herstellung von Epothilon A und B und Derivaten |
| US5969145A (en) * | 1996-08-30 | 1999-10-19 | Novartis Ag | Process for the production of epothilones and intermediate products within the process |
| DE19636343C1 (de) | 1996-08-30 | 1997-10-23 | Schering Ag | Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B |
| DE19645361A1 (de) | 1996-08-30 | 1998-04-30 | Ciba Geigy Ag | Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II |
| HU229833B1 (en) | 1996-11-18 | 2014-09-29 | Biotechnolog Forschung Gmbh | Epothilone d production process, and its use as cytostatic as well as phytosanitary agents |
| US6515016B2 (en) | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
| US6204388B1 (en) * | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| DE69734362T2 (de) * | 1996-12-03 | 2006-07-20 | Sloan-Kettering Institute For Cancer Research | Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon |
| US6660758B1 (en) | 1996-12-13 | 2003-12-09 | The Scripps Research Institute | Epothilone analogs |
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
| DE19701758A1 (de) | 1997-01-20 | 1998-07-23 | Wessjohann Ludgar A Dr | Epothilone-Synthesebausteine |
| CA2281105A1 (en) | 1997-02-25 | 1998-09-03 | Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) | Epothilones with a modified side chain |
| US5828449A (en) | 1997-02-26 | 1998-10-27 | Acuity Imaging, Llc | Ring illumination reflective elements on a generally planar surface |
| DE19713970B4 (de) | 1997-04-04 | 2006-08-31 | R&D-Biopharmaceuticals Gmbh | Epothilone-Synthesebausteine II - Prenylderivate |
| US6348551B1 (en) | 1997-04-18 | 2002-02-19 | Studiengesellschaft Kohle Mbh | Selective olefin metathesis of bifunctional or polyfunctional substrates in compressed carbon dioxide as reaction medium |
| DE19821954A1 (de) | 1997-05-15 | 1998-11-19 | Biotechnolog Forschung Gmbh | Verfahren zur Herstellung eines Epothilon-Derivats |
| DE19720312A1 (de) | 1997-05-15 | 1998-11-19 | Hoechst Ag | Zubereitung mit erhöhter in vivo Verträglichkeit |
| DE19726627A1 (de) | 1997-06-17 | 1998-12-24 | Schering Ag | Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon |
| US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| JP2001510189A (ja) | 1997-07-16 | 2001-07-31 | シエーリング アクチエンゲゼルシヤフト | チアゾール誘導体、その製造法および使用 |
| DE59814067D1 (de) | 1997-08-09 | 2007-09-06 | Bayer Schering Pharma Ag | Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung |
| BR9907647B1 (pt) | 1998-02-05 | 2014-04-01 | Novartis Ag Novartis S A Novartis Inc | Formulação farmacêutica na forma de um concentrado para infusão, o qual deve ser diluído antes da administração, e solução para infusão |
| US6194181B1 (en) * | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| FR2775187B1 (fr) | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
| NZ506742A (en) | 1998-02-25 | 2003-09-26 | Sloan Kettering Inst Cancer | Synthesis of desoxyepothilones and hydroxy acid derivative intermediates |
| DE19826988A1 (de) * | 1998-06-18 | 1999-12-23 | Biotechnolog Forschung Gmbh | Epothilon-Nebenkomponenten |
| WO2000000485A1 (de) | 1998-06-30 | 2000-01-06 | Schering Aktiengesellschaft | Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung |
| NZ511722A (en) | 1998-11-20 | 2004-05-28 | Kosan Biosciences Inc | Recombinant methods and materials for producing epothilone and epothilone derivatives |
| US6410301B1 (en) * | 1998-11-20 | 2002-06-25 | Kosan Biosciences, Inc. | Myxococcus host cells for the production of epothilones |
| AU2795000A (en) | 1998-12-22 | 2000-07-12 | Novartis Ag | Epothilone derivatives and their use as antitumor agents |
| US6780620B1 (en) * | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
| US6596875B2 (en) * | 2000-02-07 | 2003-07-22 | James David White | Method for synthesizing epothilones and epothilone analogs |
| PL349863A1 (en) | 1999-02-18 | 2002-09-23 | Schering Ag | 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use |
| CA2360452C (en) * | 1999-02-22 | 2011-07-26 | Gerhard Hoefle | C-21 modified epothilones |
| US6211412B1 (en) * | 1999-03-29 | 2001-04-03 | The University Of Kansas | Synthesis of epothilones |
| PE20010116A1 (es) | 1999-04-30 | 2001-02-15 | Schering Ag | Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion |
| TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| US6489314B1 (en) * | 2001-04-03 | 2002-12-03 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
| US6589968B2 (en) * | 2001-02-13 | 2003-07-08 | Kosan Biosciences, Inc. | Epothilone compounds and methods for making and using the same |
| US6906188B2 (en) * | 2001-04-30 | 2005-06-14 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Method for synthesizing epothilones and epothilone analogs |
| WO2003029195A1 (fr) * | 2001-09-28 | 2003-04-10 | Sumika Fine Chemicals Co., Ltd. | Intermediaires pour l'elaboration d'un derive de l'epothilone, et leur procede de production |
| US6884608B2 (en) * | 2001-12-26 | 2005-04-26 | Bristol-Myers Squibb Company | Compositions and methods for hydroxylating epothilones |
| TW200303202A (en) | 2002-02-15 | 2003-09-01 | Bristol Myers Squibb Co | Method of preparation of 21-amino epothilone derivatives |
| US6921769B2 (en) * | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| TWI291464B (en) | 2002-09-23 | 2007-12-21 | Bristol Myers Squibb Co | Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B |
-
1997
- 1997-11-18 HU HU0000497A patent/HU229833B1/hu unknown
- 1997-11-18 EP EP97951233A patent/EP0941227B2/de not_active Expired - Lifetime
- 1997-11-18 IL IL12955897A patent/IL129558A/en not_active IP Right Cessation
- 1997-11-18 DE DE59712968T patent/DE59712968D1/de not_active Expired - Lifetime
- 1997-11-18 BR BRPI9713363-9A patent/BR9713363B1/pt not_active IP Right Cessation
- 1997-11-18 NZ NZ335383A patent/NZ335383A/xx not_active IP Right Cessation
- 1997-11-18 CN CNB971998140A patent/CN1196698C/zh not_active Expired - Lifetime
- 1997-11-18 DK DK03016552T patent/DK1367057T3/da active
- 1997-11-18 EP EP03016552A patent/EP1367057B1/de not_active Expired - Lifetime
- 1997-11-18 PL PL333435A patent/PL193229B1/pl unknown
- 1997-11-18 ES ES97951233T patent/ES2221692T5/es not_active Expired - Lifetime
- 1997-11-18 CN CNB2005100062827A patent/CN100344627C/zh not_active Expired - Lifetime
- 1997-11-18 CZ CZ0175099A patent/CZ296164B6/cs not_active IP Right Cessation
- 1997-11-18 AU AU54837/98A patent/AU753546B2/en not_active Expired
- 1997-11-18 CA CA2269118A patent/CA2269118C/en not_active Expired - Lifetime
- 1997-11-18 WO PCT/EP1997/006442 patent/WO1998022461A1/de active IP Right Grant
- 1997-11-18 CZ CZ20041118A patent/CZ303422B6/cs not_active IP Right Cessation
- 1997-11-18 DE DE59711647T patent/DE59711647D1/de not_active Expired - Lifetime
- 1997-11-18 ES ES03016552T patent/ES2312695T3/es not_active Expired - Lifetime
- 1997-11-18 AT AT97951233T patent/ATE267197T1/de active
- 1997-11-18 PT PT97951233T patent/PT941227E/pt unknown
- 1997-11-18 KR KR10-1999-7004302A patent/KR100538095B1/ko not_active IP Right Cessation
- 1997-11-18 RU RU99113031/04A patent/RU2198173C2/ru active
- 1997-11-18 JP JP52320898A patent/JP4274583B2/ja not_active Expired - Lifetime
- 1997-11-18 AT AT03016552T patent/ATE408612T1/de active
- 1997-11-18 DK DK97951233T patent/DK0941227T5/da active
- 1997-11-18 PT PT03016552T patent/PT1367057E/pt unknown
-
1998
- 1998-01-21 TW TW086117334A patent/TW408119B/zh not_active IP Right Cessation
-
1999
- 1999-05-14 NO NO19992338A patent/NO319984B1/no not_active IP Right Cessation
-
2000
- 2000-02-29 HK HK00101272A patent/HK1022314A1/xx not_active IP Right Cessation
-
2004
- 2004-11-12 US US10/988,328 patent/US7067544B2/en not_active Expired - Fee Related
-
2005
- 2005-10-26 CY CY0500058A patent/CY2542B1/xx unknown
-
2006
- 2006-03-24 HK HK06103757A patent/HK1083832A1/xx not_active IP Right Cessation
- 2006-04-27 US US11/412,536 patent/US20060264482A1/en not_active Abandoned
-
2008
- 2008-04-28 US US12/110,781 patent/US20080293784A1/en not_active Abandoned
-
2009
- 2009-03-24 US US12/409,823 patent/US7846952B2/en not_active Expired - Fee Related
- 2009-05-01 US US12/434,078 patent/US7759375B2/en not_active Expired - Fee Related
-
2010
- 2010-12-06 US US12/961,447 patent/US8076490B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2269118C (en) | Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents | |
| US6288237B1 (en) | Epothilons C and D, preparation and compositions | |
| Wu et al. | N-carboxamido-staurosporine and selina-4 (14), 7 (11)-diene-8, 9-diol, new metabolites from a marine Streptomyces sp. | |
| Kunze et al. | Aurafuron A and B, new bioactive polyketides from Stigmatella aurantiaca and Archangium gephyra (myxobacteria) | |
| Amagata et al. | Absolute stereostructures of novel cytotoxic metabolites, gymnastatins A–E, from a Gymnascella species separated from a Halichondria sponge | |
| KR960012212B1 (ko) | 제초제, 그의 제조방법 및 용도 | |
| Maul et al. | Biomolecular-chemical screening: a novel screening approach for the discovery of biologically active secondary metabolites III. New DNA-binding metabolites | |
| EP0329361B1 (en) | 2-pyranone derivatives and process for production thereof | |
| KR100300152B1 (ko) | 디벤조-옥사제핀과 디벤조-디옥세핀유도체,및 항종양제로서의 이들의 용도 | |
| Anke et al. | Antibiotics from basidiomycetes. 26 Phlebiakauranol aldehyde an antifungal and cytotoxic metabolite from punctularia atropurpurascens | |
| KR20050019892A (ko) | 에포틸론 씨, 디, 이 및 에프, 그 제조방법 및 세포증식억제제와 식물 위생제로서의 이들의 용도 | |
| AU2010285723B2 (en) | A-87774 compounds or salts thereof, production method thereof and agrochemicals containing the same as active ingredient | |
| MXPA99004471A (en) | Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents | |
| JPH03504600A (ja) | ストレプトマイセス属菌類からの新規なシクリトール、その製造およびその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXP | Patent expired |